STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- AstraZeneca had four of the 12 presentations in this year's ESMO presidential sessions feature its medicines, at the congress held in Madrid this weekend.
- AstraZeneca showcased new combinations of already-approved drugs, with the presidential program using them to show the power of combining existing cancer medicines.
- AstraZeneca put a potential next targeted chemotherapy in the spotlight, alongside a mix of older standbys and new molecules that the company said could expand its arsenal of medicines further.
- Susan Galbraith, AstraZeneca's head of cancer R&D, said the ESMO presentations speak to both the breadth of the portfolio and "the depth and quality of the data that we're presenting."
Why it matters: With four of ESMO's 12 presidential presentations featuring its medicines, AstraZeneca placed a wide slice of the conference's spotlight on its oncology portfolio — approved drugs, new combinations and a targeted chemotherapy candidate — with cancer R&D head Susan Galbraith grounding that showcase in the depth and quality of its data.
Ask SkimNews
